PNC Financial Services Group’s ARS Pharmaceuticals SPRY Stock Holding History

PNC Financial Services Group’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$664	Sell	154 -862	-85%	-$5.04K	﹤0.01%	5083
2026 Q2	$8.14K	Buy	1,016 +984	+3,075%	+$8.46K	﹤0.01%	4188
2026 Q1	$257	Sell	32 -4	-11%	-$38	﹤0.01%	5007
2025 Q4	$419	Buy	+36	New	+$350	﹤0.01%	4879
2025 Q3	–	Sell	-3,935	Closed	-$68.7K	–	5226
2025 Q2	$68.7K	Buy	3,935 +25	+0.6%	+$361	﹤0.01%	2935
2025 Q1	$49.2K	Buy	3,910 +3,905	+78,100%	+$47K	﹤0.01%	3102
2024 Q4	$53	Buy	+5	New	+$70	﹤0.01%	4734
2024 Q2	–	Sell	-8	Closed	-$82	–	4910
2024 Q1	$82	Hold	8	–	–	﹤0.01%	4649
2023 Q4	$44	Buy	+8	New	+$35	﹤0.01%	4574

Other funds holding SPRY

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

General American Investors New York $1.71B AUM 30.1% 1-Year Est. Return

Pavaki Capital Management Pueblo, Colorado $294M AUM 34.46% 1-Year Est. Return

Tejara Capital London, United Kingdom $205M AUM 0.53% 1-Year Est. Return

Empire Life Investments Toronto, Ontario, Canada $1.83B AUM 33.18% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $144B AUM 22.91% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $2.18B AUM 12.5% 1-Year Est. Return

Investment Management Associates Greenwood Village, Colorado $490M AUM 6.7% 1-Year Est. Return

PNC Financial Services Group's SPRY Position: Q3 2026 in Review

PNC Financial Services Group reduced its ARS Pharmaceuticals (SPRY) stake by 85% in Q3 2026, selling an estimated $5.04K and leaving 154 shares worth $664. The position accounts for ﹤0.01% of the portfolio, ranked #5083.

PNC Financial Services Group first reported a position in SPRY in Q4 2023 and has held it in 9 quarters since. The position peaked at $68.7K in Q2 2025. 83 funds tracked by Wall St. Rank hold SPRY as of Q3 2026.

PNC Financial Services Group held 154 shares of ARS Pharmaceuticals worth $664 as of Q3 2026.
PNC Financial Services Group sold 862 ARS Pharmaceuticals shares in Q3 2026, an estimated $5.04K.
ARS Pharmaceuticals made up ﹤0.01% of PNC Financial Services Group's portfolio in Q3 2026, its #5083 holding.
PNC Financial Services Group first reported a position in ARS Pharmaceuticals in Q4 2023 and has held it in 9 quarters since.
PNC Financial Services Group's ARS Pharmaceuticals position peaked at $68.7K in Q2 2025.
83 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2026.

Based on PNC Financial Services Group's 13F filing for Q3 2026, filed 6 Nov 2026.